Results 111 to 120 of about 9,189 (185)

Table1_Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis.docx

, 2021
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384), Shanshan Long (1783180), Hao Zhou (136535), Jie Zhang (64655), Dan Li (106345), Fan Fei (1368924), Hua Yu (138267)   +6 more
core   +1 more source

In vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases

Journal of Global Antimicrobial Resistance
Objectives: Infections caused by carbapenemase-producing Gram-negative pathogens have become a significant global public health challenge due to limited treatment options.
Kengo Hayashi, Masahiro Suzuki, Yoshikazu Ishii, Yasufumi Matsumura, Kazuaki Matsumoto, Sho Saito, Yohei Doi   +6 more
doaj   +1 more source

Emergence of Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021

Emerging Infectious Diseases
Carbapenem-resistant Enterobacterales (CRE) are a major global health threat with limited treatment options. Aztreonam/avibactam is a promising therapy against metallo-β-lactamase (MBL)–producing and other CRE, but emerging resistance threatens its ...
Tengfei Long, Arianne Lovey, Lillie Sanborn, Yanan Zhao, Zackery P. Bulman, Yi-Tsung Lin, Liang Chen   +6 more
doaj   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistance

Precision Clinical Medicine, 2022
Wu, Shikai, Zong, Zhiyong
openaire   +2 more sources

Avibactam pharmacokinetic/pharmacodynamic targets [PDF]

, 2018
Avibactam is a novel non--lactam -lactamase inhibitor that has been approved in the United States and Europe for use in combination with ceftazidime.
Riccobene, T, Shampa Das, Newell, P, Paul Newell, Ian A. Critchley, Todd Riccobene, Critchley, IA, Das, S, Nichols, WW, Wright W. Nichols   +9 more
core   +1 more source

Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type β-lactamases in PBP3-modified Escherichia coli

Purpose: Carbapenemase-producing Enterobacterales are a growing threat, and very few therapeutic options remain active against those multidrug resistant bacteria.
Helsens, Nicolas, Le Terrier, Christophe, Sadek, Mustafa, Nordmann, Patrice, Poirel, Laurent   +4 more
core   +1 more source

A comparative evaluation of aztreonam-avibactam and ceftazidime-avibactam plus aztreonam for infections due to MBL-producing Enterobacterales

International Journal of Infectious Diseases
Objectives: Aztreonam-avibactam (ATM-AVI) and ceftazidime-avibactam plus aztreonam (CAZ/AVI-ATM) represent therapeutic strategies for infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales.
Simone Giuliano, Chiara Moreal, Jacopo Angelini, Alejandro J. Vila, Robert A. Bonomo, Pranita D. Tamma, Carlo Tascini   +6 more
doaj   +1 more source

Comparison of agar-based methodologies to broth disc elution for the detection of aztreonam susceptibility in the presence of ceftazidime-avibactam

Microbiology Spectrum
The combination of aztreonam and ceftazidime-avibactam is a proven treatment option for infections caused by metallo-beta-lactamase (MBL)-expressing gram-negative organisms. Restoration of aztreonam susceptibility in the presence of ceftazidime-avibactam
Teslin S. Sandstrom, Andra Banete, Alice Kanyua, Kevin M. Davis, Susan M. Poutanen   +4 more
doaj   +1 more source

Implantação de metodologia para avaliação da atividade in vitro da Ftazidima/Avibactam associado a Aztreonam contra enterobactérias produtora de Metalo-β-Lactamase [PDF]

, 2020
A emergência da resistência bacteriana foi classificada, pela Organização Mundial de Saúde, como uma das três principais ameaças à saúde pública do século XXI, podendo causar 300 milhões de mortes prematuras até 2050.
Cabral, Luciana Lemes Zamalha
core